Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | PRKDC | P78527 | 1/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10734 | 0.85 | PIK3CG (0.49) | PIK3CGCYP2C9PRKDCPIK3CAPIK3CD | |
| SCHEMBL12710092 | 0.85 | PIK3CG (0.49) | PIK3CGCYP2C9PRKDCPIK3CAPIK3CD | |
| SCHEMBL12710084 | 0.85 | PIK3CG (0.63) | PIK3CGCYP2C9PRKDCPIK3CAPIK3CD | |
| SCHEMBL12710085 | 0.83 | ABL1 (0.50) | PIK3CGCYP2C9PRKDCPIK3CAPIK3CD | |
| SCHEMBL9990 | 0.83 | PIK3CG (0.68) | PIK3CGCYP2C9PRKDCPIK3CAPIK3CD | |
| SCHEMBL12710081 | 0.82 | ABL1 (0.49) | PIK3CGCYP2C9PRKDCPIK3CAPIK3CD | |
| SCHEMBL10234 | 0.82 | PIK3CG (0.49) | PIK3CGCYP2C9PRKDCPIK3CAPIK3CD | |
| SCHEMBL12991990 | 0.78 | PIK3CG (1.00) | PIK3CGCYP2C9PRKDC | |
| SCHEMBL12710086 | 0.76 | PIK3CG (0.45) | PIK3CGCYP2C9PRKDCPIK3CAPIK3CD | |
| SCHEMBL13739 | 0.73 | PIK3CG (0.48) | PIK3CGCYP2C9PRKDCPIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488511-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041634-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041634-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | PIK3CG 3/4885CYP2C9 2078/4885PRKDC 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.